Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Can a plant produce anti-SARS-CoV-2 antibody?

Cancer Vaccines: A Concoction Strategy to fight Leukemia

Ministry of AYUSH | Siddha Central Research Biotech Research Recruitment

Can a plant produce anti-SARS-CoV-2 antibody?
  • BiotechToday
  • World

Can a plant produce anti-SARS-CoV-2 antibody?

bioxone October 16, 2020October 15, 2020

Prama Ghosh, Amity University Kolkata

The current critical situation due to COVID–19 has resulted in excessive centralization of biomanufacturing capacities which is a matter of great concern. But on the brighter side, sharing of scientific data and information globally at an unprecedented speed has helped strengthen our ability in developing new solutions based on technology. Speaking of which, the manufacture of bioreagents specifically recombinant antibodies from plant bio-factories is being explored. 

For this purpose, the production of six different monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana is tested in academic labs and a matter of weeks. For designing the antibodies, DNA sequence information was made rapidly available among other data sources by other groups in preprint publications. Engineered single-chain fragments of monoclonal antibodies were fused to a human gamma Fc which was transiently expressed using a viral vector. Recombinant SARS-CoV-2 N protein and its Receptor Binding Domain (RBD) in plants were produced simultaneously. These were further used to test the binding capacity of the antibodies. 

The results indicated that anti-SARS-CoV-2 monoclonal antibodies could be easily produced in gram amounts in a little more than 6 weeks by using N. benthamiana used as a production platform in repurposed greenhouses with little infrastructure requirements. With the help of similar procedures, diagnostic reagents can also be produced which will provide rapid therapeutic responses.

Also read: Cancer Vaccines: A Concoction Strategy to fight Leukemia

Reference: Pilot production of SARS-CoV-2 related proteins in plants: a proof of concept for rapid repurposing of indoors farms into biomanufacturing facilities, Borja Diego-Martin, Beatriz González, Marta Vazquez-Vilar, Sara Selma, Rubén Mateos-Fernández, Silvia Gianoglio, Asun Fernández-del-Carmen, Diego Orzaez, doi: https://doi.org/10.1101/2020.10.13.331306

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged a tobacco plant Antibody bio-factory bio-manufacture bioreagent COVID-19 human gamma monoclonal antibody Nicotiana benthamiana recombinant DNA recombinant DNA techniques recombinant protein SARS-CoV-2 vector viral vector

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Ministry of AYUSH | Siddha Central Research Biotech Research Recruitment

bioxone October 16, 2020

-Shristi Sharma, Team bioXone Siddha Central Research Jobs – Biotech & Mol Bio JRF Vacancy. MSc Biotechnology and Molecular Biology Job Openings. Junior Research Fellow Vacancy at Siddha Central Research Institute. Interested and eligible applicants can check out all of the details on the same below: Name of the Post: Junior Research Fellow(Pharmacology) No. of […]

Related Post

  • BiotechToday
  • World

Can a specific MicroRNA prove to be fatal for KRAS mediated NSCLC?

bioxone September 21, 2020September 24, 2020

-Biswadeep Sen, Amity University Kolkata We all can agree to the fact that despite the advancement in the treatments and technology, Lung Cancer is still, by far, the leading cause of cancer death worldwide. Amongst the multiple oncogenic driver alterations discovered the one with the most frequent aberration is KRAS mutation. To make matters worse, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • India
  • World

Covid Update: Moderna Vaccine on the Horizon!

bioxone October 20, 2020October 20, 2020

Chitra Roy, University of Calcutta An American biotechnology company ‘Moderna’, based in Cambridge, Massachusetts focuses on the discovery and development of drugs in addition to vaccine technologies. They exclusively use messenger RNA (mRNA) therapeutics and designs vaccines to create a completely new generation of transformative medicines. Against COVID-19, Moderna has developed its mRNA vaccine candidate […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Schizophrenia risk linked with ancestry of the patients

BioTech Today August 14, 2021August 13, 2021

Soumya Shraddhya Paul, Amity University, Noida Schizophrenia (SCZ) is a severe mental illness that affects 0.5–1% of the global population. Positive (hallucinations and delusions), negative (anhedonia, alogia, and avolition), and cognitive deficits are the major symptoms of SCZ (impaired working memory and executive function). SCZ exerts a significant economic burden on society and poses a […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy